Property | Value |
?:abstract
|
-
BACKGROUND: Several RT-qPCR kits are available for SARS-CoV-2 diagnosis, some of them with Emergency Use Authorization (EUA) by FDA, but most of them lacking of proper evaluation studies due to covid19 emergency. OBJECTIVE: We evaluated Viasure RT-qPCR kit (CerTest Biotec, Spain) for SARS-CoV-2 diagnosis using FDA EUA 2019-nCoV CDC kit (IDT, USA) as gold standard. RESULTS: Although we found the lack of RNA quality control probe as the main limitation for the Viasure kit, the sensitivity was 91.9% and the specificity was 100%. The limit of detection (LOD) was 2000 copies/mL and 1000 copies/mL for Viasure and IDT kits, respectively. CONCLUSIONS: Viasure RT-qPCR kit is a relatively reliable tool for SARS-CoV-2 diagnosis but improvement of an alternative RT-qPCR reaction for RNA extraction quality control as RNaseP is recommended.
|
is
?:annotates
of
|
|
?:creator
|
|
?:doi
|
-
10.1016/j.virol.2020.10.010
|
?:doi
|
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/27eda3bba5f1bd268f7145f36dbb7fcdcc68581c.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7673214.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis.
|
?:type
|
|
?:year
|
|